Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FENhance
PACTR202212815145545Phase 3Recruiting
- Sponsor
- Roche
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Fenebrutinib with Teriflunomide active comparator (2 arms). Primary endpoint: Annualized relapse rate. Started Feb 2023; status: recruiting.
02
Drugs
fenebrutinibteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on PACTR202212815145545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202212815145545.